Skip to main content
S&P 5007,551.81-0.45%DOW51,461.90-1.21%NASDAQ25,978.42-0.01%BTC$76,173.00+0.74%ETH$2,416.48+0.77%GOLD$4,313.30-1.69%OIL$101.66-0.75%
Smart Investors Daily
IN

NASDAQ · INM

InMed Pharmaceuticals Inc.

Healthcare · Biotechnology

$1.28

Up+$0.00 (+0.00%)

Updated Sep 17, 2026, 12:04 AM

SID Score

3.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.52M
P/E ratio
-0.17
Dividend yield
0.00%
52-week range
$0.58 – $2.50
Volume
79.06K
Avg. volume
346.51K

Price performance

INM price history

1M range · 19 trading sessions · Daily adjusted prices

INM closed at $1.28 after 19 trading sessions, down 19.50% for the selected period.

Last close
$1.28
Period change
-19.50%
Period low
$1.28
Period high
$1.59
Daily close
View OHLC price history
INM OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Sep 15, 2026$1.27$1.31$1.25$1.2879.06K
Sep 14, 2026$1.29$1.32$1.27$1.3058.46K
Sep 11, 2026$1.33$1.35$1.29$1.2928.14K
Sep 10, 2026$1.31$1.34$1.29$1.3120.5K
Sep 9, 2026$1.3099$1.33$1.28$1.3152.82K
Sep 8, 2026$1.36$1.39$1.31$1.3363.67K
Sep 4, 2026$1.3394$1.3966$1.33$1.389.54K
Sep 3, 2026$1.341$1.41$1.32$1.3345.54K
Sep 2, 2026$1.36$1.40$1.33$1.3519.98K
Sep 1, 2026$1.35$1.35$1.30$1.32104.48K
Aug 31, 2026$1.36$1.42$1.35$1.3590.05K
Aug 28, 2026$1.425$1.43$1.38$1.38111.95K
Aug 27, 2026$1.422$1.45$1.405$1.4329.82K
Aug 26, 2026$1.48$1.48$1.36$1.4360.91K
Aug 25, 2026$1.44$1.47$1.385$1.44118.47K
Aug 24, 2026$1.48$1.61$1.41$1.43164.41K
Aug 21, 2026$1.58$1.615$1.45$1.4671.61K
Aug 20, 2026$1.57$1.65$1.54$1.5863.94K
Aug 19, 2026$1.46$1.6315$1.45$1.5986.11K

Latest INM news

The latest Smart Investors Daily articles mentioning INM.

Stock researchCompany · Overview

INM research

Overview

Company profile and research snapshot.

Company profile

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
INM recent ratings
DateFirmRatingTarget
Nov 29, 2021HC Wainwright & Co.Buy—
Feb 16, 2021Roth CapitalBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 9, 2026

InMed Reports Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Vancouver, British Columbia--(Newsfile Corp. - September 9, 2026) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reported financial results for its fiscal year ended June 30, 2026.The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2026, are available at www.inmedpharma.com,...

Yahoo · Jul 6, 2026

InMed Pharmaceuticals and Mentari Therapeutics Announce Amendment to Merger Agreement and Filing of Registration Statement on Form S-4

Vancouver, British Columbia and San Francisco, California--(Newsfile Corp. - July 6, 2026) - InMed Pharmaceuticals, Inc. (NASDAQ: INM) ("InMed" or the "Company") today announced that it has entered into an amendment (the "Amendment") to the previously announced definitive merger agreement (the "Agreement") for an all-stock transaction with Mentari Therapeutics, Inc. ("Mentari"), a privately-held biotechnology company developing therapies for migraine prevention, Indigo Merger Sub Corp., a...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By